OR Manager, Inc., and ECRI Institute have joined in a collaboration to bring OR Manager readers periodic articles on topics such as medical technology management and procurement, risk management, and patient safety. ECRI Institute is an independent nonprofit that researches the best approaches to improving patient care.
Opioids are the second most frequent class of medications to cause adverse drug reactions in hospitalized patients, trailing only loop diuretics.
ECRI Institute recently published new data about this critical issue in its Deep Dive™: Opioid Use in Acute Care, based on its analysis of 7,200 events submitted to the ECRI Institute Patient Safety Organization (PSO). Below is a sample event reported to ECRI Institute PSO:
An emergency department tech mistakenly entered 60 mg immediate-release morphine, twice a day, as the medication that the patient took before admission, instead of 60 mg extended-release morphine. Both the prescribing nurse practitioner and the pharmacist overrode clinical decision support warnings indicating that the order exceeded the maximum dose. Fortunately, a staff member noticed the error prior to harm reaching the patient.
Oversedation and respiratory depression, which can lead to death if not quickly recognized and reversed, are prime concerns. In reviews of medication utilization, administration of naloxone—an agent used to reverse the effects of opioids—is often considered a general indicator that the patient suffered opioid-induced respiratory depression, although not every instance of naloxone administration represents a case of preventable opioid-induced respiratory depression.
One estimate suggests that naloxone is given to about 0.2% to 0.7% of patients receiving opioids postoperatively. Although these percentages might seem low, even low percentages can extrapolate to large numbers of patients.
These and other findings from the Deep Dive analysis are shown in the sidebar on pp 18-19. For the full report, go to https://www.ecri.org/opioids.
To improve opioid management, consider the following questions:
• How might improving the safety of opioid use support our mission, vision, and goals?
• Do our culture, staffing, and work environment support safe opioid use?
• Who is responsible for opioid safety in our organization?
• In what ways do we monitor the safety of opioid use?
• How well do we perform, in terms of both outcomes and processes for opioid safety? What are our goals?
• Do we engage in analysis, discussion, and learning from opioid-related adverse events?
• Have we undertaken quality improvement initiatives related to opioids?
• What concerns do frontline staff have regarding opioid safety?
• How do we help set realistic patient expectations regarding pain in the hospital?
• What alternatives to opioids do we offer to manage patients’ pain in the hospital?
• In recent years, are we seeing more patients with risk factors for opioid-induced respiratory depression, such as sleep apnea? Do our approaches adequately account for these risk factors?
• What commonalities are there among patients who experience opioid-related adverse drug events?
• How do we support ongoing education and training related to opioids?
• What measures, including policies, processes, and technologies, are in place to support safe opioid use?
• How effective are our methods of monitoring patients receiving opioids?
• Have we made prevention and detection of controlled substance diversion an organizational priority?
• Does our approach to inpatient opioid use comply fully with applicable laws, regulations, and standards?
• How might a high-profile opioid-related incident, such as a drug diversion, affect our reputation?
• Do providers and staff follow best practices related to opioids? If not, why not?
• Do clinicians feel pressured to prescribe and administer opioids to achieve patient satisfaction?
• What do our frontline staff do on a daily basis to facilitate safe use of opioids, and how can we support and build on those activities?
ECRI institute PSO is one of the first PSOs to be federally certified under the provisions of the Patient Safety and Quality Improvement Act (PSQIA). PSQIA gives healthcare organizations a way to voluntarily share their safety surveillance data in a protected environment so PSOs can aggregate and analyze the data. The law also charges PSOs with the responsibility to share the findings and lessons learned. The release of ECRI Institute PSO DEEP Dive™: Opioid Use in Acute Care is in keeping with that responsibility (https://www.ecri.org/Pages/Opioids-Deep-Dive.aspx).
Reprinted with permission.©2018 ECRI Institute. ✥